Navigation Links
Regulus Reports Second Quarter 2014 Financial Results and Recent Highlights
Date:8/6/2014

e study is being conducted in the Netherlands and has four parts: (i) a single ascending-dose study in healthy volunteer subjects; (ii) a multiple-ascending dose study in healthy volunteer subjects; (iii) a single-dose drug-drug interaction study of RG-101 in combination with an approved oral direct-acting antiviral ("DAA") in healthy volunteer subjects; and (iv) a single-dose study in HCV patients to assess the safety and viral load reduction.  The primary objective of the study is to evaluate safety and tolerability and the secondary objectives are to evaluate pharmacokinetics, viral load reduction and any impact an oral DAA may have on the pharmacokinetics of RG-101.  Up to 100 healthy volunteer subjects and HCV patients are planned to be enrolled in the Phase I study.  Under the 'Clinical Map Initiative', Regulus expects to report human proof-of-concept results from Part IV of the Phase I study by the end of 2014.
  • Strengthened Leading IP Estate; Expanded Coverage on anti-miR-122 for HCV.  The U.S. Patent and Trademark Office granted a patent in Regulus' exclusively licensed 'Sarnow' patent estate for claims related to targeting miR-122 for the treatment of HCV in combination with other anti-viral therapies. 
  • Advanced Preclinical microRNA Portfolio, Independently and with Strategic Partners.  Regulus continued to advance several additional programs, both independently and with its strategic alliance partners, targeting miR-21 and microRNA-221 for the treatment of hepatocellular carcinoma, targeting microRNA-19 for oncology indications and targeting microRNA-103/107 for the treatment of metabolic diseases.  Additionally, Regulus continued to pursue several undisclosed microRNA targets, namely for orphan disease and oncology indications, to expand its therapeutics pipeline.  Under the 'Clinical Map Initiative', Regulus expects to nominate a third microRNA candidate for clinical development (either independ
    '/>"/>

  • SOURCE Regulus Therapeutics Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Regulus Enters Into New Collaboration Agreement with Biogen Idec to Identify microRNA Biomarkers in Multiple Sclerosis
    2. Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome
    3. Regulus Announces Addition to NASDAQ Biotechnology Index
    4. Regulus Reports Third Quarter 2013 Financial Results and Recent Highlights
    5. Regulus Presents Positive Preclinical Data Demonstrating that microRNA-21 Plays an Important Role in Alport Syndrome
    6. Regulus Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
    7. Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca and Selection of a New Pre-Clinically Validated microRNA Oncology Target
    8. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
    9. Regulus Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
    10. Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
    11. Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2015)... More than 1,500 substance abuse prevention and ... Indianapolis Aug. 2-6 for Community ... Institute . The week-long training, held at the JW ... our nation,s biggest public health challenges – youth drug ... a one-of-a-kind intensive training opportunity, offering more than 70 ...
    (Date:7/31/2015)... , July 31, 2015 The Physician-Patient ... release on July 28, 2015, "Surviving Your Hospital ... Fundraising for Patient Safety." A sentence ... should read: "PPAHS is a member ... on Opioids. For more information on the National Coalition ...
    (Date:7/31/2015)... July 31, 2015  Xcelience, a contract development ... has made a structured cash investment in Powdersize, ... in milling, micronization and powder size classification within ... Powdersize,s business while simultaneously adding a complete set ... of capabilities. "As we continue ...
    Breaking Medicine Technology:Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3
    ... May 29, 2012  DebMed®, creator of the world,s ... on the World Health Organization,s (WHO,s) Five Moments, ... has increased hand hygiene compliance by five to ... using the DebMed GMS™ electronic monitoring system and supporting ...
    ... Inc. (Nasdaq: NBIX ) announced today that Kevin ... be presenting at the Jefferies 2012 Global Healthcare Conference in ... on Tuesday, June 5 at 2:00 p.m. Eastern Time / ... may be accessed on the Company,s website at http://www.neurocrine.com ...
    Cached Medicine Technology:Greenville Hospital System Achieves Dramatic Improvement in Hand Hygiene Compliance Rates Using New Technology from DebMed® 2Greenville Hospital System Achieves Dramatic Improvement in Hand Hygiene Compliance Rates Using New Technology from DebMed® 3
    (Date:7/31/2015)... ... , ... Cosmetic Town has proven itself as the leader ... procedures including, but not limited to, abdominoplasty, blepharoplasty, rhinoplasty and septoplasty. The ... , Staying up to date with the latest cosmetic trends has never ...
    (Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Creating one ... , is in pursuit of a visionary image that goes beyond the boundaries of ... New Hope IVF has reached extraordinary heights with dependable patient support, affordable treatments, unending ...
    (Date:7/31/2015)... ... 31, 2015 , ... The Mount Sinai Health System will work with Columbia ... of related, experimental treatments. The collaboration moves into the next phase with the recent ... of five state licenses to produce and dispense medical marijuana. , Mount Sinai ...
    (Date:7/31/2015)... ... July 31, 2015 , ... Recently, ZKB filed another ... Western Division (Case No. 3:15-cv-00397) involving the Implanon® contraceptive implant . , ... of their Implanon® implants, inability to locate the implants, unsuccessful and invasive attempts ...
    (Date:7/31/2015)... ... 2015 , ... Florida Hospital Tampa has started treating select ... targeted delivery of fluids to selected sites in the peripheral vascular system. Patients ... the device that provides direct, local delivery of chemotherapy to the pancreas. This ...
    Breaking Medicine News(10 mins):Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 3Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4
    ... agents could make it possible to "see" tumors in ... compounds, derived from inhibitors of the enzyme cyclooxygenase-2 (COX-2) ... have broad applications for cancer detection, diagnosis and treatment. ... in a paper featured on the cover of the ...
    ... Dennis Thompson HealthDay Reporter , FRIDAY, Oct. 7 ... not know it, but the process that created a new ... Blood contained in the umbilical cord and placenta is ... to treat leukemia, lymphoma and many other life-threatening diseases, according ...
    ... Parents of young caffeine consumers take heed: that high-calorie ... obesity risk. In fact, according to a double-blind, placebo-controlled ... response to caffeine may predict how he or she ... in risk for abuse of other more serious drugs ...
    ... "stop and smell the roses," it,s likely your brain is ... New research from Northwestern Medicine offers strong evidence that the ... smells -- setting up a mental expectation of a scent ... important because it provides animals -- in this case, humans ...
    ... HealthDay Reporter , WEDNESDAY, Oct. 5 (HealthDay News) -- Steve ... to personal computers, then the iPod, the iPhone and the iPad, ... was 56. "Apple has lost a visionary and ... the company said in a statement it posted on its website ...
    ... Gardner HealthDay Reporter , THURSDAY, Oct. 6 (HealthDay ... has once again focused attention on cancers of the pancreas, ... Jobs, tumor was actually one with a better prognosis than ... Patrick Swayze. In fact, the type of cancer that ...
    Cached Medicine News:Health News:Imaging agents offer new view of inflammation, cancer 2Health News:As One Life Starts, Another May Be Saved 2Health News:As One Life Starts, Another May Be Saved 3Health News:As One Life Starts, Another May Be Saved 4Health News:Jonesing for java: Could caffeine use predict risk for cocaine abuse? 2Health News:Sniffing out the brain's predictive power 2Health News:Steve Jobs, Visionary Leader of Apple Inc., Dies at 56 2Health News:Steve Jobs, Visionary Leader of Apple Inc., Dies at 56 3Health News:Pancreatic Cancer: A Stubborn Foe 2
    ... Craftsmanship have produced the finest ... Ocutek® now makes them available ... the coveted Meisterbrief certificate, which ... qualified to become Ocutek instrument ...
    ... Centuries of German Craftsmanship have ... in the world. Ocutek now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
    ... Centuries of German Craftsmanship have ... in the world. Ocutek now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
    1mm by 7mm horizontal punch. Flat serrated handle. Overall length 87mm....
    Medicine Products: